Q1 · MEDICINE
Article
Author: Picon, Sylvain ; Culot, Maxime ; Hoguet, Vanessa ; Baron, Morgane ; Leroux, Florence ; Deprez, Benoit ; Sevin, Emmanuel ; Duplan, Isabelle ; Touche, Véronique ; Piveteau, Catherine ; Lestavel, Sophie ; Hennuyer, Nathalie ; Villoutreix, Bruno O ; Gosselet, Fabien ; Roussel, Pascal ; Chaput, Ludovic ; Boulahjar, Rajaa ; Lasalle, Manuel ; Biela, Alexandre ; Lipka, Emmanuelle ; Dumont, Julie ; Deprez-Poulain, Rebecca ; Dorchies, Emilie ; Staels, Bart ; Vallez, Emmanuelle ; Descat, Amandine ; Charton, Julie ; Tailleux, Anne
A novel series of potent agonists of the bile acid receptor TGR5 bearing a dihydropyridone scaffold was developed from a high-throughput screen. Starting from a micromolar hit compound, we implemented an extensive structure-activity-relationship (SAR) study with the synthesis and biological evaluation of 83 analogues. The project culminated with the identification of the potent nanomolar TGR5 agonist 77A. We report the GLP-1 secretagogue effect of our lead compound ex vivo in mouse colonoids and in vivo. In addition, to identify specific features favorable for TGR5 activation, we generated and optimized a three-dimensional quantitative SAR model that contributed to our understanding of our activity profile and could guide further development of this dihydropyridone series.